[go: up one dir, main page]

AU2001239052A1 - Compositions for prevention and treatment of dementia - Google Patents

Compositions for prevention and treatment of dementia

Info

Publication number
AU2001239052A1
AU2001239052A1 AU2001239052A AU3905201A AU2001239052A1 AU 2001239052 A1 AU2001239052 A1 AU 2001239052A1 AU 2001239052 A AU2001239052 A AU 2001239052A AU 3905201 A AU3905201 A AU 3905201A AU 2001239052 A1 AU2001239052 A1 AU 2001239052A1
Authority
AU
Australia
Prior art keywords
dementia
prevention
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239052A
Inventor
Allen I. Bain
Alexander Zolotoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Network Ltd
Original Assignee
Immune Network Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Network Ltd filed Critical Immune Network Ltd
Publication of AU2001239052A1 publication Critical patent/AU2001239052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001239052A 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia Abandoned AU2001239052A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18731000P 2000-03-06 2000-03-06
US60187310 2000-03-06
PCT/CA2001/000271 WO2001066096A2 (en) 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia

Publications (1)

Publication Number Publication Date
AU2001239052A1 true AU2001239052A1 (en) 2001-09-17

Family

ID=22688461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239052A Abandoned AU2001239052A1 (en) 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia

Country Status (3)

Country Link
US (1) US20030144255A1 (en)
AU (1) AU2001239052A1 (en)
WO (1) WO2001066096A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical compositions containing donepezil hydrocholoride
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005009427A1 (en) * 2003-07-29 2005-02-03 Cell Signals Inc. Curative medicine for allergosis
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP2008525313A (en) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-dementia drug stabilization method
JP5731094B2 (en) * 2005-02-11 2015-06-10 スティーブン・ウィルスStephen WILLS Treatment of microvascular diseases with acetylcholinesterase inhibitors
RS51822B (en) * 2005-04-04 2012-02-29 Eisai R. &D. Management Co. Ltd. DIHYDROPYRIDINE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND Dementia
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP2010520154A (en) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 AMPA receptor antagonists and NMDA receptor antagonists for neurodegenerative diseases
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
JP6217938B2 (en) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
HK1251980B (en) 2015-05-22 2020-07-10 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
WO1993024118A1 (en) * 1992-05-29 1993-12-09 The University Of British Columbia Dapsone and promin for the treatment of dementia
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
WO2001066096A2 (en) 2001-09-13
US20030144255A1 (en) 2003-07-31
WO2001066096A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2002364364A1 (en) Method of treating apoptosis and compositions thereof
AUPR105400A0 (en) Processes and compositions for water treatment
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2001233081A1 (en) Composition for treatment of stress
MXPA03006043A (en) Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis.
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002218461A1 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2003301819A1 (en) Compositions and methods for prevention of photoaging
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002228500A1 (en) Methods and compositions for reducing or preventing onset of milk fever
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU2335601A (en) Treatment or prevention of diarrhea
AU2002221169A1 (en) Herbal composition for_the prevention and treatment of dementia
AU4388899A (en) Novel compositions for the treatment of atherosclerosis and related conditions